GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
23.98
+1.19 (5.22%)
Dec 15, 2025, 4:00 PM EST
GSK plc Revenue
GSK plc had revenue of 7.99B GBP in the quarter ending June 30, 2025, with 1.29% growth. This brings the company's revenue in the last twelve months to 31.63B, up 0.59% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.63B GBP
Revenue Growth
+0.59%
P/S Ratio
2.27
Revenue / Employee
460.90K GBP
Employees
68,629
Market Cap
98.09B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | -9.40B | -27.58% |
| Dec 31, 2020 | 34.10B | 345.00M | 1.02% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
GSK plc News
- 1 day ago - UK approves GSK's twice-yearly asthma drug - Reuters
- 1 day ago - GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Nasdaq
- 1 day ago - Dividend Income: Lanny's October 2025 Summary - Seeking Alpha
- 4 days ago - GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade) - Seeking Alpha
- 4 days ago - GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe - GuruFocus
- 4 days ago - GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Nasdaq
- 4 days ago - GSK Gains CHMP Recommendation for Nucala in COPD Treatment - GuruFocus
- 4 days ago - GSK's Depemokimab Receives CHMP Approval Recommendation for Asthma and CRSwNP - GuruFocus